Despite FDA Approval, Near Term U.S. Mircera Launch Appears Doubtful
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen has legal hold on the commercialization of Roche’s long-acting erythropoiesis stimulating agent for now.